Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
17.7M
-
Number of holders
-
10
-
Total 13F shares, excl. options
-
219K
-
Shares change
-
-1.36M
-
Total reported value, excl. options
-
$173K
-
Value change
-
-$1.3M
-
Number of buys
-
8
-
Number of sells
-
-3
-
Price
-
$0.71
Significant Holders of Kairos Pharma, LTD. - Common Stock, par value $0.001 per share (KAPA) as of Q2 2025
13 filings reported holding KAPA - Kairos Pharma, LTD. - Common Stock, par value $0.001 per share as of Q2 2025.
Kairos Pharma, LTD. - Common Stock, par value $0.001 per share (KAPA) has 10 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 219K shares
of 17.7M outstanding shares and own 1.23% of the company stock.
Largest 10 shareholders include XTX Topco Ltd (62.7K shares), SevenBridge Financial Group, LLC (44.3K shares), Aptus Capital Advisors, LLC (44.3K shares), GEODE CAPITAL MANAGEMENT, LLC (21.8K shares), TWO SIGMA SECURITIES, LLC (13.6K shares), HRT FINANCIAL LP (13.2K shares), UBS Group AG (9.46K shares), CITIGROUP INC (5.5K shares), Tower Research Capital LLC (TRC) (3.8K shares), and BANK OF AMERICA CORP /DE/ (51 shares).
This table shows the top 10 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.